An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.
Matthew Skoronski
Advertisement
Senior Director–PRMA (pricing, reimbursement and market access), Indegene
Articles by Matthew Skoronski
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer
2
Pharma Partnerships Expand as Eli Lilly Announces Strategic Collaborations with MeiraGTx and SanegeneBio
3
Wegovy Demonstrates Reduction in Liver Injury in MASH Patients
4
CMS Unveils Initiative to Cut Medicaid Drug Costs and Expand Access to Affordable Medications
5
